Update on renal osteodystrophy: Pathogenesis and clinical management

American Journal of the Medical Sciences

Volumn 317, Issue 4, 1999, Pages 251-260

  Sakhaee, Khashayar ^a   Gonzalez, Gilberto B ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM CHANNEL STIMULATING AGENT; SEVELAMER; VITAMIN D DERIVATIVE;

BONE BIOPSY; BONE DENSITY; BONE DISEASE; BONE TURNOVER; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE CLASSIFICATION; DRUG EFFECT; HUMAN; OSTEOMALACIA; PATHOGENESIS; PHOSPHATE INTAKE; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM;

EID: 0141526958     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9629(15)40516-6     Document Type: Conference Paper

References (66)

1. Drueke T, Kubrusly M. Pathogenesis of secondary hyperparathyroidism of chronic renal failure [editorial]. J Nephrol 1994;7:139-47.
2. Slatopolsky E, Delmez J. Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 1994;23:229-36.
3. Herbelin A, Urena P, Nguyen AT, et al. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 1991;39:954-60.
4. Memoli B, Libetta C, Rampino T, et al. Hemodialysis related induction of interleukin-6 production by peripheral blood mononuclear cells. Kidney Int 1992;42:320-6.
5. Herbelin A, Nguyen AT, Zingraff J, et al. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha. Kidney Int 1990;37:116-25.
6. Langub MC Jr, Koszwski NJ, Turner HV, et al. Bone resorption and mRNA expression of IL-6 and IL-6 1-receptor in patients with renal osteodystrophy. Kidney Int 1996;50: 515-20.
7. Falchetti A, Bale AE, Amorosi A, et al. Progress of uremic hyperparathyroidism involves allelic loss of chromosome 11. J Clin Endocrinol Metab 1993;76:139-44.
8. Albright F, Baird PC, Cope O, et al. Studies on the physiology of the parathyroid glands. IV. Renal complications of hyperparathyroidism. Am J Med Sci 1934;187:49-65.
9. Malluche HH, Ritz E, Lange HP, et al. Bone histology in incipient and advanced renal failure. Kidney Int 1976;9:355-62.
10. Bricker NS, Slatopolsky E, Reiss E, et al. Calcium, phosphorus and bone in renal disease and transplantation. Arch Intern Med 1969;123:543-53.
11. Slatopolsky E, Caglar S, Pennell JP, et al. On the pathogenesis of hyperparathyroidism in chronic experimental insufficiency in the dog. J Clin Invest 1971;50:492-9.
12. Portale AA, Booth BE, Halloran BP, et al. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxy-vitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 1984;73:1580-9.
13. Lopez-Hilker S, Dusso A, Rapp N, et al. Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am J Physiol 1990;259:F432-7.
14. Slatopolsky E, Finch J, Denda M, et al. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996;97:2534-40.
15. Fraser DR, Kodicek E. Unique biosyntheses by kidney of a biologically active vitamin D metabolite. Nature 1970;228: 764-6.
16. Portale AA, Booth BE, Tsae HC, et al. Reduced plasma concentration of 1,25-dihydroxyvitamin D in children with moderate renal insufficiency. Kidney Int 1982;21:627-32.
17. Pitts TO, Piraino BH, Mitro R, et al. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate and severe renal failure. J Clin Endocrinol Metab 1988; 67:876-81.
18. Malluche HH, Werner E, Ritz E. Intestinal absorption of calcium and whole-body calcium retention in incipient and advanced renal failure. Miner Electrolyte Metab 978;1:263-70.
19. Brumbaugh PF, Hughes MR, Haussler MR. Cytoplasmic and nuclear binding components for 1,25-dihydroxyvitamin D3 in chick parathyroid glands. Proc Natl Acad Sci USA 1975;72:4871-5.
20. Silver J, Russel J, Sherwood ML. Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci USA 1985;82:4270-3.
21. 3H-1,25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure. N Engl J Med 1987;316:1573-7.
22. Fukuda N, Tanaka H, Tominaga Y, et al. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993;92:1436-42.
23. 2+-sensing receptor from bovine parathyroid. Nature 1993;366:575-80.
24. 2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Endocrinol Metab 1996;81:1598-606.
25. Dewhirst FE, Ago JM, Peros WJ, et al. Synergism between parathyroid hormone and interleukin-1 in stimulating bone resorption in organ culture. J Bone Miner Res 1987;2: 127-34.
26. Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med 1995;333:166-74.
27. 2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989;35:1049-56.
28. Brown EM, Wilson RE, Eustman RC, et al. Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. J Clin Endocrinol Metab 1982;54:172-9.
29. Kremer R, Bolivar I, Goltzman D, et al. Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells. Endocrinology 1989;125:935-41.
30. Arnold A, Brown MF, Urena P, et al. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 1995;95:2042-54.
31. 3 intake: emergence of an idiopathic adynamic bone disease not related to aluminum. Nephron 1989;53:93-101.
32. Bordier PJ, Tun-Chot S, Eastwood JB, et al. Lack of histological evidence of vitamin D abnormality in the bones of anephric patients. Clin Sci 1973;44:33-41.
33. Schmidt-Gayk H, Schmitt W, Grawunder C, et al. 25-hydroxyvitamin D in nephrotic syndrome. Lancet 1977;2: 105-8.
34. Ott SM, Maloney NA, Coburn JW, et al. The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy. N Engl J Med 1982;307:709-13.
35. Alfrey AC. Aluminum. Adv Clin Chem 1983;23:69-91.
36. Chan Y-L, Alfrey AC, Posen S, et al. Effect of aluminum on normal and uremic rats: tissue distribution, vitamin D metabolites, and quantitative bone histology. Calcif Tissue Int 1983;35:344-51.
37. Leiberherr M, Grosse B, Cournot-Witmer G, et al. In vitro effects of aluminum on bone phosphatases: a possible interaction with bPTH and vitamin D3 metabolites. Calcif Tissue Int 1982;34:280-4.
38. Pun KK, Ho PWM, Lau P. Effects of aluminum on the parathyroid hormone receptors of bone and kidney. Kidney Int 1990;37:72-8.
39. Sherrard DJ, Herza G, Pei Y, et al. The spectrum of bone disease in end-stage renal failure - an evolving disorder. Kidney Int 1993;43:436-42.
40. Coburn JW. Mineral metabolism and renal bone disease: effects of CAPD verses hemodialysis. Kidney Int 1993; 40(suppl):S92-S100.
41. Watson P, Lazowski D, Han V, et al. Parathyroid hormone restores bone mass and enhances osteoblast insulin-like growth factor I gene expression in ovarectomized rats. Bone 1995;16:357-65.
42. Hughes FJ, Howells GL. Interleukin-11 inhibits bone formation in vitro. Calcif Tissue Int 1993;53:362-4.
43. Orloff JJ, Soifer NE, Fodero JP, et al. Accumulation of carboxy-terminal fragments of parathyroid hormone-related protein in renal failure. Kidney Int 1993;43:1371-6.
44. Bushinsky DA, Godring JM, Coe FL. Cellular contribution to pH mediated calcium flux in neonatal mouse calvaria. Am J Physiol 1985;248:F785-9.
45. Malluche HH, Monier-Faugere MC. The role of bone biopsy in the management of patients with renal osteodystrophy. J Am Soc Nephrol 1994;4:1631-42.
46. Alfrey AC. Aluminum metabolism. Kidney Int 1986;(Suppl 18):29:S8-S11.
47. Sheikh MS, Maguire JA, Emmet M, et al. Reduction of dietary phosphorus absorption by phosphorus binders: A theoretical in vitro and in vivo study. J Clin Invest 1989;83:66-73.
48. Slatopolsky E, Weerts C, Norwood K, et al. Long-term effects of calcium carbonate and 2.5 meq/liter calcium dialysate on mineral metabolism. Kidney Int 1989;36:897-03.
49. Delmez JA, Slatopolsky E. Clinical review 20: recent advances in the pathogenesis and therapy of uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1991;72:735-9.
50. Slatopolsky E, Weerts C, Theilan J, et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 1984;74:2136-43.
51. Andress DL, Norris KC, Coburn JW, et al. Intravenous calcitriol in treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989;321:274-9.
52. Reichel H, Szabo A, Uhl J, et al. Intermittent versus continuous administration of 1,25-dihydroxyvitamin D3 in experimental renal hyperparathyroidism. Kidney Int 1993; 44:1259-65.
53. Quarles LD, Yohay DA, Carroll BA, et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 1994;45:1710-21.
54. Levine BS, Song M. Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol 1996;7:488-96.
55. Fernandez E, Llach F. Guidelines for dosing of intravenous calcitriol in dialysis patients with hyperparathyroidism. Nephrol Dial Transplant 1996;11(Suppl 3):96-101.
56. Coburn JW, Frazo J. Calcitriol in the management of renal osteodystrophy. Semin Dial 1996;9:316-26.
57. Felsenfeld AJ. Considerations for treatment of secondary hyperparathyroidism in renal failure. J Am Soc Nephrol 1997;8:993-04.
58. Tan AU, Levine BS, Mazess R. Effective suppression of parathyroid hormone by 1-hydroxyvitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 1997;51:317-23.
59. Fukagawa M, Kitaoka M, Kurokawa K. Renal failure and hyperparathyroidism. In: Feldman D, Glorieux F, and Pike JW, editors. Vitamin D. San Diego: Academic Press; 1997. p. 1227-39.
60. 2D3 and 22-oxacalcitriol on phosphate and calcium metabolism. Kidney Int 1993;43:561-6.
61. 2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kid Dis 1997;30:105-12.
62. Malluche H, Faugere MC. Renal bone disease 1990: An unmet challenge for the nephrologist. Kidney Int. 1990; 38: 193-211.
63. Chertow GM, Burke SK, Lazarus M, et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997;29:66-71.
64. Antonsen JE, Sherrard DJ, Andress DL. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Kidney Int 1998;53:223-7.
65. Wada M, Ishii H, Furuya Y, et al. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 1998;53: 448-54.
66. Sherrard DJ. Calcimimetics in action. Kidney Int 1998;53: 510-1.